JACKSONVILLE, Fla., Oct. 26, 2006 (PRIMEZONE) -- Phlo Corporation (Pink Sheets:PHLC) announced today that one of its affiliates (the "Company") has entered into a distribution agreement with Blackard Group, Inc. for the distribution in certain domestic and international markets of the Company's rehydration beverages. Blackard has significant domestic and international real estate interests as well as manufacturing and distribution operations. An affiliate of Blackard will conduct its distribution activities pursuant to the agreement (the "Distributor").
The Distributor will distribute the Company's AQUIS(tm) Rapid Response Rehydration beverages domestically in the elite athlete market segment, primarily in the areas of organized sports, team sales, and institutional sales, and to General Nutrition Centers. The Distributor will distribute both the newly developed AQUIS(tm) ready-to-drink products as well as powdered AQUIS(tm).
The distribution agreement provides for the required purchase by the Distributor of AQUIS(tm) products during the initial 12-month period of the term of the agreement aggregating approximately $12.7 million in order to maintain its distribution rights under the agreement.
AQUIS(tm) rehydration products deliver electrolyte payloads through the Company's Micro-Encapsulation Delivery System ("MEDS"), which enables actives to cross cellular membranes and rapidly distribute to target tissues. The MEDS technology involves encapsulation of the payloads for fast and efficient delivery into the bloodstream. The micro-encapsulation of the actives in tiny, biologically-active nano-particles (invisible to the eye) creates protective "coats" allowing immediate, rapid absorption, beginning through the membranes of the mouth. The micro-encapsulated payloads are absorbed by all membranes with which they come into contact. The coats also protect the active payload from the hostile environment of the stomach and produce the sustained release of the active payloads.
AQUIS(tm) also contains the Company's VEP/PPC technology, which involves the effective delivery to the bloodstream of payloads that repair and protect the cellular mechanisms which maintain vigorous longevity.
Phlo is a biotechnology company and a manufacturer and marketer of products (primarily liquids) containing patented and patent-pending biotechnologies. Phlo is focusing its technology generation and acquisition efforts on those technologies related to enhancing cognition and personal performance, reducing the effects of aging, and preventing or ameliorating cancer.
Certain statements made herein that are not historic constitute "forward-looking" statements within the meaning of the Private Litigation Reform Act of 1995 and may contain words such as "anticipate," "believe," "expect," "future," "may," "will," "should," "plan," "projected," "intend," and similar expressions to identify such forward-looking statements. Such statements are based on a number of assumptions and on information and estimates supplied to Phlo Corporation by sources currently available to it. Such assumptions and estimates are subject to uncertainties, contingencies, and other factors, many of which are beyond Phlo Corporation's control. Actual results may differ materially from the statements set forth above.